FCM
TGTX icon

Frontier Capital Management’s TG Therapeutics TGTX Stock Holding History

Frontier Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3M Buy
+368,813
New +$15.1M 0.19% 184
2022
Q2 		– Sell
-618,821
Closed -$5.88M – 278
2022
Q1 		$5.88M Buy
618,821
+462,203
+295% +$5.35M 0.05% 241
2021
Q4 		$2.98M Buy
+156,618
New +$4.07M 0.02% 265

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Frontier Capital Management's TGTX Position: Q2 2026 in Review

Frontier Capital Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 368,813 shares worth $20.3M. The stake represents 0.19% of the portfolio and ranks #184 among its holdings. This is a return to the name: Frontier Capital Management previously reported a position in TGTX as recently as Q1 2022.

Frontier Capital Management first reported a position in TGTX in Q4 2021 and has held it in 3 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Frontier Capital Management held 368,813 shares of TG Therapeutics worth $20.3M as of Q2 2026.
  • TG Therapeutics was a new Frontier Capital Management position in Q2 2026.
  • TG Therapeutics made up 0.19% of Frontier Capital Management's portfolio in Q2 2026, its #184 holding.
  • Frontier Capital Management first reported a position in TG Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Frontier Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.